@article{cd6e2dde23e848e3911613fb777f25cc,
title = "Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol",
keywords = "antipsychotic medication, cognition, double-blind, estrogen, negative syndrome, performance, persistent symptoms, postmenopausal women, raloxifene, randomised controlled trial, reliability, scale, schizophrenia, sex-differences, PERFORMANCE, Estrogen, Schizophrenia, RELIABILITY, SCALE, POSTMENOPAUSAL WOMEN, PERSISTENT SYMPTOMS, NEGATIVE SYNDROME, COGNITION, Antipsychotic medication, Randomised controlled trial, DOUBLE-BLIND, ESTROGEN, Raloxifene, SEX-DIFFERENCES",
author = "B.A. Brand and {de Boer}, J.N. and S.B.J.O. Ophuis and M.I.E. Slot and {De Wilde}, B. and K.C.E.E.R. Catthoor and A.J. Goverde and P.R. Bakker and M.C. Marcelis and K.P. Grootens and J.J. Luykx and S.M. Heringa and C.S. Weickert and I.E.C. Sommer and T.W. Weickert",
year = "2020",
month = dec,
day = "1",
doi = "10.1016/j.conctc.2020.100681",
language = "English",
volume = "20",
journal = "Contemporary Clinical Trials Communications",
issn = "2451-8654",
publisher = "Elsevier Inc.",
}